Multicenter retrospective study on perceived effectiveness, reported side effects, and cognitive outcomes of SSRIs in 22q11.2 deletion syndrome.

22q11.2 deletion syndrome (22q11DS) markedly increases risk of psychiatric disorders, including anxiety and mood disorders, and is associated with a spectrum of cognitive impairment, from borderline functioning to intellectual disability, with cognitive decline frequently reported.

In the longitudinal analyses, intellectual quotient (intellectual quotient) trajectories were compared between 101 selective serotonin reuptake inhibitors-treated and 213 selective serotonin reuptake inhibitors-untreated participants (4-34 years) using mixed-model regression analyses.